Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy - Wikidata - wikimedia - TriplyDB

Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy

Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy

http://www.wikidata.org/entity/Q38945259

about

Enhancement of Cetuximab-Induced Radiosensitization by JAK-1 Inhibition.HER3, but Not HER4, Plays an Essential Role in the Clinicopathology and Prognosis of Gastric Cancer: A Meta-Analysis A human IgG-like bispecific antibody co-targeting epidermal growth factor receptor and the vascular endothelial growth factor receptor 2 for enhanced antitumor activity Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance)Let-7a enhances the sensitivity of hepatocellular carcinoma cells to cetuximab by regulating STAT3 expression.Targeted therapies in breast cancer: New challenges to fight against resistance.Pharmacologic treatment options for advanced epithelial skin cancer.Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab.Treatment of head and neck cancer in the elderly.A phase 1 study combining the HER3 antibody seribantumab (MM-121) and cetuximab with and without irinotecan.Overcoming resistance to cetuximab with honokiol, a small-molecule polyphenol.A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer.Positive prognostic value of HER2-HER3 co-expression and p-mTOR in gastric cancer patients.MicroRNA-9 enhances sensitivity to cetuximab in epithelial phenotype hepatocellular carcinoma cells through regulation of the eukaryotic translation initiation factor 5A-2.Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines.HER3 protein expression in relation to HER2 positivity in patients with primary colorectal cancer: clinical relevance and prognostic value.

P2860

Q35803714-0BF06B38-33FF-424C-BBF8-71B17499E732 Q36106546-18729CFF-3D26-4444-8D42-3902DC8DA25C Q36844361-FD321925-4FF8-49C1-B58E-A979D4F90D42 Q37321131-3A98D03B-C1D2-4171-8318-5D3D1F2C0248 Q37469797-9C4B9613-C703-4A90-97C5-4D8D55F41B02 Q37743048-FF0EE719-BA96-4A7C-B2F6-2D4444D33F63 Q38509273-7B91EF9A-B6CF-4684-BC03-40F606BE5E8A Q38757863-91FF7792-CD43-4D66-A986-3910D4E781F1 Q38958367-837F8F9E-B762-451D-8F6E-4C95F4A9CF93 Q45959066-474FBA76-9403-494A-911B-40894768689C Q46278768-3C7A34A7-E060-44FA-8622-619F032E6431 Q47158524-4040194D-43AD-4E8C-B401-D6FCF702163A Q47301897-959C2953-6831-4B3E-AAC4-90AE610A3CC7 Q49335206-E1D1855E-2977-48FD-8400-38C1764B5CC9 Q52617485-0CAE93C6-7C26-4125-BBAC-408B1ADBCE77 Q54286661-1D4A5E9D-6DC0-4963-A5B9-55F2C607AC1E

P2860

Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy

http://www.wikidata.org/entity/Q38945259

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

Overcoming acquired resistance ...... rs with antibody-based therapy

@en

type

label

Overcoming acquired resistance ...... rs with antibody-based therapy

@en

prefLabel

Overcoming acquired resistance ...... rs with antibody-based therapy

@en

P1433

Q38945259-A502117B-37CB-49C2-9006-3FBEA9C60E70

P1476

Q38945259-E26EED7C-D955-4F4F-A745-F9D467E8206A

P2093

Q38945259-0291D51D-352D-4CB1-91A1-8A472972207B

Q38945259-047D5F27-42A1-4B4F-80FF-839054E2B67B

Q38945259-131906BF-F5E3-48C9-BE5D-4542C4875FEC

Q38945259-2D6E0131-0B6E-4252-883C-BED7BB7F4BA6

Q38945259-56DE06BA-18C6-477A-98A0-80E1D92C998F

Q38945259-AC133C9C-160D-442E-9E81-D74044071EA7

Q38945259-B227DA1C-0997-401F-AF4F-79558CCCB188

Q38945259-CAD1B2BB-45B9-4C0B-A903-D78B540D2370

Q38945259-F4CFD90F-7BEA-4F30-90F0-083C8F0D6610

P2860

Q38945259-0FD22842-6A85-4135-A714-09CAD293072F

Q38945259-10EDC566-954D-48E9-B666-7775EF81FB9D

Q38945259-11F8CA20-AD39-477F-BF9E-A8F062E8DFE3

Q38945259-158B50E9-BE1A-4726-B141-CACB666FDFAB

Q38945259-1C0BFBDD-04A5-4A18-A004-E695F806B751

Q38945259-21D21B2A-46B5-4A9B-9AA3-821DA4F2107B

Q38945259-226E3467-14C8-4E72-9E89-AA76CA429A0C

Q38945259-2355C6AD-816D-406D-87C3-D93C95695D4D

Q38945259-294CAD49-4085-47B8-A487-D9F4F2F90DFB

Q38945259-2C1A675D-9DDF-4271-B97F-92546473A3FE

P2888

Q38945259-21626F2B-4683-4AD7-A07D-101D73BA9596

P304

Q38945259-370ACD77-0BA3-49A6-AF5B-EB37DB87E192

P31

Q38945259-EA986924-7B8D-4555-822D-B22C866AEA91

P356

Q38945259-345A4CA6-7DC1-4E8A-AC5A-1580011FA1DA

P478

Q38945259-4EF38034-5382-4C03-9A4F-FE799812576C

P50

Q38945259-26939C8B-9305-4573-A284-F2E5961C2A87

P577

Q38945259-907A2872-7B10-480D-9825-F992698908C6

P5875

Q38945259-62742CF2-FDD1-4BAF-B52C-9B67F44C6C72

P6179

Q38945259-9FA5D474-5BE2-4F7E-9840-0E5349ADCED9

P698

Q38945259-E1CC72C8-9323-4215-AEC7-BCB7173B8791

P921

Q38945259-AD0D68E8-98A8-4B1F-B11F-0DEF90894B9E

P932

Q38945259-25DC8954-3073-4D94-8596-07EE6D7D97FB

P356

1476-4598-13-242

P1433

Molecular Cancer

P1476

Overcoming acquired resistance ...... rs with antibody-based therapy

@en

P2093

Deric L Wheeler

http://www.w3.org/2001/XMLSchema#string

Evan J Huppert

http://www.w3.org/2001/XMLSchema#string

Hannah E Pearson

http://www.w3.org/2001/XMLSchema#string

Harsh Bahrar

http://www.w3.org/2001/XMLSchema#string

John P Coan

http://www.w3.org/2001/XMLSchema#string

Mari Iida

http://www.w3.org/2001/XMLSchema#string

Megan M Starr

http://www.w3.org/2001/XMLSchema#string

Neha Luthar

http://www.w3.org/2001/XMLSchema#string

Toni M Brand

http://www.w3.org/2001/XMLSchema#string

P2860

ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Blocking NRG1 and other ligand-mediated Her4 signaling enhances the magnitude and duration of the chemotherapeutic response of non-small cell lung cancer.

Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor rec

HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

EGFR-targeted therapy in malignant glioma: novel aspects and mechanisms of drug resistance.

P2888

1476-4598-13-242

P304

242

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1476-4598-13-242

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-10-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

267744183

http://www.w3.org/2001/XMLSchema#string

P6179

1029644172

http://www.w3.org/2001/XMLSchema#string

P698

25344208

http://www.w3.org/2001/XMLSchema#string

P921

P932

4283113

http://www.w3.org/2001/XMLSchema#string